Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
贝伐单抗治疗复发性和持续性卵巢癌或腹膜癌的妇科肿瘤组 II 期试验中的预测性和预后性血管生成标志物
期刊:Gynecologic Oncology
影响因子:4.1
doi:10.1016/j.ygyno.2010.08.016
Han Ernest S, Burger Robert A, Darcy Kathleen M, Sill Michael W, Randall Leslie M, Chase Dana, Parmakhtiar Basmina, Monk Bradley J, Greer Benjamin E, Connelly Patrick, Degeest Koen, Fruehauf John P
